Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...
Zacks Investment Research on MSN
Why Vertex Pharmaceuticals (VRTX) is a top momentum stock for the long term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Fintel reports that on December 5, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a ...
Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...
The stock has fallen from a peak back in April.
On November 18, 2025, ToolGen, Inc. (“ToolGen”) filed a complaint (“Complaint”) in the District of Massachusetts alleging infringement of its ...
These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the transformative potential of CASGEVY,” said Carmen Bozic, M.D ...
NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback